# Convergent Genomics

> Convergent Genomics is a South San Francisco genomic diagnostics company that turns a cup of urine into a cancer readout. Its UroAmp test sequences 60 high-impact urothelial genes plus the whole genome, then runs machine learning over the results to detect, monitor, and predict bladder cancer - in one study, flagging future disease up to 12 years before a cystoscopy could. Founded in 2015 out of Oregon Health & Science University and Illumina Accelerator, it sells to urologists and oncologists as a non-invasive alternative to scoping the bladder.

- **Founded:** 2015
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Brian Slingerland (CEO and Co-Founder), Trevor Levin (Founder, President & Chief Scientific Officer)
- **Team size:** 26 employees
- **Products:** UroAmp, UroAmp MRD, Enhanced Preservation Media (EPM)
- **Notable:** Published research showing UroAmp predicted bladder cancer up to 12 years before clinical diagnosis, correct in 66% of future-cancer cases at 94% specificity (rising to ~90% sensitivity when diagnosis came within five years)., Study showing UroAmp detected bladder cancer that both cystoscopy and urine cytology missed., Peer-reviewed validation in the Journal of Clinical Medicine using 423 urine samples and 91 tumor/urine sample pairs.

## Products & services

- **UroAmp** — A non-invasive genomic urine test that sequences 60 high-impact urothelial cancer genes and broadly measures the whole genome, then applies machine learning to detect urothelial cancer and estimate a Genomic Disease Burden (GDB) score. First available in limited release in 2021.
- **UroAmp MRD** — A minimal residual disease and recurrence-monitoring application of UroAmp for patients after definitive treatment, tracking tumor mutations over time and reporting FGFR3 and MSI status relevant to FDA-approved therapies such as erdafitinib and pembrolizumab.
- **Enhanced Preservation Media (EPM)** — Patented collection media that stabilizes urine DNA for up to 14 days at room temperature, enabling mail-in and remote sample collection.

## Achievements

- Published research showing UroAmp predicted bladder cancer up to 12 years before clinical diagnosis, correct in 66% of future-cancer cases at 94% specificity (rising to ~90% sensitivity when diagnosis came within five years).
- Study showing UroAmp detected bladder cancer that both cystoscopy and urine cytology missed.
- Peer-reviewed validation in the Journal of Clinical Medicine using 423 urine samples and 91 tumor/urine sample pairs.
- Reported low-grade tumor sensitivity of 67% versus 12.5% for cytology, and high-grade sensitivity of 100% versus 50% for cytology.
- CLIA-certified and CAP-accredited clinical laboratory operations.

## Latest updates

- **2023-07** — Published data indicating UroAmp could predict bladder cancer up to 12 years before clinical signs appear, drawn from long-banked urine samples.
- **2023-09** — Released study showing UroAmp detected bladder cancer not found by cystoscopy or urine cytology.
- **2023-05** — Presented new UroAmp studies at the American Urological Association (AUA) Annual Meeting.

## Links

- Website: https://convergentgenomics.com
- LinkedIn: https://www.linkedin.com/company/convergent-genomics

---

Profile page: https://yespress.io/convergent-genomics
Published by YesPress — https://yespress.io
Last updated: 2026-08-20